What is IVERIC bio, Inc. (ISEE)?

IVERIC bio, Inc. (ISEE) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of ISEE?

The current price of ISEE is $39.95. Prices are updated in real time on Stocks360.

What is ISEE's price-to-earnings (PE) ratio?

ISEE's trailing twelve-month PE ratio is -27.55, based on current price and earnings per share data available on Stocks360.

What is ISEE's market capitalization?

ISEE's market capitalization is $5,512,180,830.00, placing it in the mid-cap tier.

IVERIC bio, Inc. (ISEE)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$39.95

Market Cap

$5.51B

PE (TTM)

-27.55

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.10

Day Range

$39.85 – $39.98

52-wk Range

$9.39 – $39.99

Avg Volume

N/A

Volume

10.80M

IVERIC bio, Inc. (ISEE) is a publicly traded company in the Healthcare sector. Latest price: $39.95. Market cap $5.51B. Trailing PE -27.55. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Jul 25, 2023

EPS $-0.41 vs est. $-0.49

Beat by $0.08

Proprietary Signals

Signal snapshot temporarily unavailable.

About IVERIC bio, Inc.

IVERIC bio, Inc. is a biopharmaceutical enterprise focused on identifying and advancing innovative therapeutic solutions for eye conditions, with a particular emphasis on age-related and rare inherited retinal diseases (IRDs). A cornerstone of its development pipeline is Zimura, an inhibitor targeting complement factor C5. This compound is currently undergoing investigation for geographic atrophy (GA), a severe form of dry age-related macular degeneration (AMD). Zimura's clinical progression includes the GATHER1 trial, which has successfully concluded its Phase 2/3 stage, and the GATHER2 trial, which is presently in Phase 3. The company's portfolio also features STAR (identified as OPH2005), a candidate in Phase 2b clinical trials for addressing Leber congenital amaurosis type 10 (LCA10) and autosomal recessive Stargardt disease (STGD1). Additionally, IVERIC bio is developing IC-500, a high-temperature requirement A serine peptidase 1 protein inhibitor intended for GA and other forms of age-related retinal degeneration. Other programs include IC-100, aimed at rhodopsin-mediated autosomal dominant retinitis pigmentosa, and IC-200, designed for IRDs stemming from mutations in the BE…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-27.55×
P/S (TTM)	0.00×
P/B	9.04×
PEG	0.71×
P/FCF (TTM)	-33.51×
EV / EBITDA	-28.08×
EV / Sales	0.00×
Earnings Yield	-3.63%
Free Cash Flow Yield	-2.98%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$5.13B
Net Income (TTM)	-$200.34M
Free Cash Flow (TTM)	-$162.36M
Net Debt	-$378.54M
Working Capital	$627.24M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-39.26%
Return on Invested Capital	-28.49%